KIDNEY TRANSPLANTATION

This study looks at how well the shingles vaccine (Shingrix) works in adults with kidney failure who are waiting for a kidney transplant. Researchers want to see if giving an extra dose after the transplant boosts the immune response. About 132 participants will be followed for u…

This study tests a new drug called ALXN2030 in 45 adults who have had a kidney transplant and are experiencing antibody-mediated rejection (AMR). The goal is to see if the drug can help resolve signs of rejection seen on a kidney biopsy after one year of treatment. Participants w…

This study tests whether dipyridamole, a drug usually used for heart conditions, can raise low phosphate levels in kidney transplant recipients. Researchers will give the drug to 90 adult patients when their phosphate drops below normal. The goal is to see if it improves phosphat…

This early-phase trial tests whether a powerful immune reset using a patient's own stem cells can clear the antibodies that block them from receiving a kidney transplant. Ten highly sensitized adults with end-stage kidney disease will undergo intense conditioning to wipe out thei…

This study tests whether monitoring levels of a harmless virus called TTV can help doctors personalize immune-suppressing drugs for kidney transplant patients. The goal is to prevent long-term complications like infections, cancer, and organ rejection. About 600 adults who receiv…

This study is testing whether a kidney from a genetically modified pig can safely work in people with end-stage renal disease who cannot get a human kidney. Up to 50 participants will receive the pig kidney and be followed for at least 24 weeks to check survival, kidney function,…

This early-stage trial tests a new cell therapy called Eight Treg in 9 people receiving a kidney from a living donor. The therapy uses the patient's own immune cells, grown in a lab, to help the body accept the new kidney without strong anti-rejection drugs. The main goal is to c…

This phase 2 trial tests whether a single infusion of a patient's own regulatory T cells (TRK-001) can prevent the immune system from attacking a new kidney. 34 living-donor kidney transplant recipients will either receive standard anti-rejection drugs alone or those drugs plus t…

This study tests a genetically modified pig kidney (called the 10 GE Xenokidney) in 50 adults with end-stage kidney disease who cannot get a human kidney transplant or face a long wait. The goal is to see if the pig kidney works safely and well, improving survival and quality of …

This study looks at whether older kidney transplant patients (55 and up) can safely stop taking one of their standard immunosuppressant drugs, mycophenolate mofetil (MMF). About 350 participants will be randomly assigned to either continue MMF or stop it, while staying on other m…

This study tests a treatment called extracorporeal phototherapy (ECP) for people whose kidney transplants are failing due to chronic antibody-mediated rejection. ECP involves taking a patient's blood cells, treating them with a light-activated drug and UVA light, then returning t…

This early-phase trial tests whether a stomach acid drug called vonoprazan fumarate can reduce delayed graft function, a common complication where a new kidney doesn't work right away. About 47 first-time kidney transplant recipients will take the drug for seven days after surger…

This study tests whether a 12-week home-based exercise program is safe and practical for adults aged 60 and older who are waiting for a kidney transplant. Participants will either receive usual care plus a physical activity tracker, or usual care plus the tracker and online exerc…

This study tests a 6-week online program called the Chronic Disease Self-Management Program (CDSMP) for people in Israel living with a kidney transplant or cancer. The program teaches practical skills like managing symptoms, setting health goals, and communicating with doctors. R…